IBRX ImmunityBio, Inc.

The GA-Courtenay Special Situations Fund is an investment fund managed by Green Ash Partners. The fund focuses on special situations and high-growth equities. You can download the July letter here. The fund reported a 13.8% decline in July, bringing its year-to-date performance to -10.0%. The fund attributed the decline to an unusual liquidity-driven dislocation across […]

IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.

ImmunityBio Inc. (NASDAQ:IBRX) saw its share price jump by 9.94 percent on Tuesday to finish at $9.29 apiece following a high-profile meeting between its founder, Dr. Patrick Soon-Shiong, and Turkish President Recep Tayyip Erdogan, fueling optimism around the listed firm’s planned expansion into Turkey. The Turkish government posted a photo of Erdogan and Soon-Shiong on […]

Soon-Shiong owned 65.5% of ImmunityBio as of its April proxy record date.

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nant Capital’s investment of up to $22.3 million in a PIPE into PDS Biotech, along with Patrick Soon Shiong’s new board seat there, pushed ImmunityBio (NasdaqGS:IBRX) up 6% on Monday and sharpened focus on his broader immunotherapy plans. ImmunityBio’s share price has cooled slightly in the very short term, with a 1-day share price return of 2.75% and a 7-day share price return of 1.81%. However, the 30-day and 90-day share price returns of 7.53% and 16.45% suggest momentum is still building...

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

PDS Biotech said it completed the initial close of a Nant Capital-led PIPE of up to $22.3 million and seated Soon-Shiong on its board — tying IBRX’s public face to a second immunotherapy platform.

ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.

A new patent application covers using Anktiva to restore immune cells depleted by cancer treatments.

Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.

Patrick Soon-Shiong said the trial has been fully accrued and passed its one-year mark.

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.

Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.

ImmunityBio stock has delivered a very strong 321.9% return over the past three years, yet current valuation checks and recent price weakness raise questions about how much of the recent progress is already reflected in the share price. Over the last three years, ImmunityBio has returned 321.9%, which puts recent short term pullbacks into the context of a very strong multi year run. Approval for ANKTIVA in the UAE and growing commercial traction can support higher revenue expectations, while...

In the past week, ImmunityBio, Inc. received marketing authorization in the United Arab Emirates for ANKTIVA across BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, while reporting second-quarter 2026 revenue of US$51.24 million and a net loss of US$230.38 million. The UAE decision gives ANKTIVA its broadest approval yet across the full spectrum of BCG-unresponsive bladder cancer and checkpoint-refractory lung cancer, extending ImmunityBio’s...

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

ImmunityBio’s record quarterly revenue of $51.2 million beat Wall Street’s estimates of $49.7 million, driven by the increased sales of Anktiva.

ImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

On July 29, UAE regulators approved ImmunityBio’s main cancer drug ANKTIVA for two indications, sparking a rally the next day.

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio (NASDAQ:IBRX) shares climbed 7. 5% on Thursday after the company announced that the United Arab Emirates had granted marketing approval for ANKTIVA in two cancer indications, further expanding the therapy’s international regulatory reach.

The UAE becomes Anktiva’s fifth regulatory jurisdiction, expanding its footprint to 34 countries and boosting ImmunityBio’s global push.

Investors are also watching for partnership or buyout catalysts as ImmunityBio expands Anktiva internationally and builds its global NK-cell platform.

Weekend chatter focused on ImmunityBio’s quiet July, with some bulls calling the silence the “quiet before the kraken.”

ImmunityBio (IBRX) is back in focus after its stock surged 282.7% year to date, as investors weigh speculation around Anktiva’s role in bladder cancer treatment alongside ongoing regulatory and valuation questions. See our latest analysis for ImmunityBio. Recent trading shows that momentum in ImmunityBio’s share price has cooled in the near term, with a 7 day share price return down 12.16%, following a year to date share price return of 282.67% and a 1 year total shareholder return of...

ImmunityBio’s stock has surged 282.7% year to date, yet its overall valuation checks sit at a mixed 3 out of 6. This leaves investors weighing a powerful momentum story against signals that do not clearly flag the shares as cheap or expensive. The year to date gain of 282.7% suggests expectations around ImmunityBio have reset sharply higher. Fresh buyers are now paying a far richer price than they would have earlier in the year. Speculation around Anktiva’s potential role in bladder cancer...

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.

Sheets Smith Wealth Management cut its IBRX stake by 7.2% to 512,572 shares.